Case series:afatinib combined with bevacizumab

2 trials

Sponsors

National Cancer Center/Cancer Hospital & Shenzhen Hospital, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Conditions

NSCLClung cancer

Phase 4

Real-world study for sequential therapy with afatinib combined with bevacizumab as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC)

Active, not recruitingChiCTR2000029034

National Cancer Center/Cancer Hospital & Shenzhen Hospitallung cancer

Start: 2020-02-01Updated: 2020-01-13

Unknown Phase

Bevacizumab combined with afatinib for first-line treatment of locally advanced or advanced EGFR mutation-positive NSCLC patients: the effectiveness and safety database management platform construction project

Active, not recruitingChiCTR2000034451

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNSCLC

Start: 2020-07-06Updated: 2020-07-06